Clinical trials: Resistant Depression, Treatment
Healthy
A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers
This study will evaluate the safety, tolerability and pharmacokinetics of BCI-838, its metabolite BCI-632 and several new pro-drugs in healthy male subjects.
- Trial name
- NCT01546051
- Testing
- BCI-838, BCI-1038, BCI-1206 & BCI-1283
- Where
- Netherlands
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- BrainCells Inc.
Treatment Resistant Depression
A Biomarker-Guided, Randomized, Placebo-Controlled Efficacy and Safety Study of Liafensine in Patients With TRD
This study was conducted as a randomized, double-blind, placebo-controlled, multi-center Phase 2b study. Approximately 180 subjects with treatment resistant depression who meet all eligibility criteria will be enrolled.
- Trial name
- ENLIGHTEN (NCT05113771)
- Testing
- Liafensine
- Where
- 45 sites in United States, Canada
- Volunteers
- 197 people
- Sponsor
- Denovo Biopharma LLC
Depressive Disorder, Treatment-Resistant, Depressive Disorder, Major
Sevoflurane for Treatment-Resistant Depression
This study intends to carry out a prospective, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subanesthetic sevoflurane for treatment-resistant depression.
- Trial name
- NCT05008939
- Testing
- Sevoflurane
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Shanghai First Maternity and Infant Hospital
Depressive Disorder, Treatment-Resistant
A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression
The purpose of this study is to evaluate how well esketamine nasal spray works in improving depressive symptoms in participants with treatment resistant depression (TRD).
- Trial name
- NCT07053345
- Testing
- Esketamine 56 mg, Esketamine 84 mg
- Where
- 6 sites in South Korea
- Volunteers
- 47 people
- Sponsor
- Janssen Korea, Ltd., Korea
Major Depressive Disorder, Treatment Resistant Depression
40 Hz Light Neurostimulation for Patients With Depression (FELIX)
Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory.
- Trial name
- NCT05680220
- Testing
- Neurostimulation System (NSS): Active Setting
- Where
- Denmark
- Volunteers
- 60 people
- Sponsor
- Klaus Martiny
Major Depressive Disorder
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant Depression
The purpose of this study is to assess the efficacy of esketamine compared with placebo in improving symptoms of depression in patients with treatment resistant depression.
- Trial name
- NCT01640080
- Testing
- Esketamine
- Where
- 9 sites in Belgium, Germany and 1 more
- Volunteers
- 30 people
- Sponsor
- Janssen Research & Development, LLC
Depressive Disorder, Treatment-Resistant
Glutamate and Opioid Mechanisms of Antidepressant Response to Ketamine
The overarching aim of this research is to determine the acute effects of ketamine on brain glutamate, functional connectivity and cerebral blood flow in treatment-resistant depression, explore whether the effects are attenuated…
- Trial name
- GO-MARK (NCT04977674)
- Testing
- Naltrexone, Ketamine
- Where
- United Kingdom
- Volunteers
- 27 people
- Sponsor
- King's College London
Major Depressive Disorder, Treatment Resistant Depression
Investigation of the Effects of Repetitive Transcranial Magnetic Stimulation on Cognition in Depression
According to the World Health Organization, MDD is attributed as the leading cause of disability worldwide, leaving 300 million individuals affected.
- Trial name
- NCT03977038
- Testing
- repetitive transcranial magnetic stimulation
- Where
- Canada
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Depressive Disorder
Cerebral Neuroinflammation During Major Depressive Episode
the investigators make the following assumptions: 1) neuroinflammation in MDD can be measured by the [18 F ] DPA- 714 ; 2) it is accompanied by anatomical and functional changes in the frontal subcortical loops, strongly involved…
- Trial name
- InflaDep (NCT03314155)
- Testing
- Cerebral neuroinflammation evaluation
- Where
- 4 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University Hospital, Toulouse
Moderate Depression, Major Depressive Disorder
Neuromodulation of Different Doses to Treat TRD Guided by pBFS Technique
The aim of this study is to explore the effectiveness and safety of different doses of neural regulation under the guidance of pBFS technology in improving symptoms in patients with moderate to severe depressive disorders.
- Conditions
- Moderate Depression, Major Depressive Disorder, Severe Depression
- Trial name
- NCT06112652
- Testing
- 4 session rTMS, 6 session rTMS, 8 session rTMS
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Changping Laboratory
Major Depressive Disorder
Repetitive Transcranial Magnetic Stimulation (rTMS) for Treatment Resistant Depressive Disorder
Major Depressive Disorder (MDD) is one of the most prevalent mental illnesses in North America, in which 30% - 40% fail to respond to conventional treatment.
- Trial name
- NCT01515215
- Testing
- Repetitive Transcranial Magnetic Stimulation
- Where
- Canada
- Volunteers
- 107 people
- Sponsor
- Centre for Addiction and Mental Health
Treatment Resistant Depression (TRD)
Treatment Resistant Depression and Vagus Nerve Stimulation
Depression is a common illness, affecting 17% of the population over the course of a lifetime. A third of depressions relapses and progresses to recurrence and resistance to treatments.
- Trial name
- DepVNS (NCT05952674)
- Testing
- Vagus Nerve Stimulation (VNS), Best Medical Treatment
- Where
- 24 sites in France
- Volunteers
- 166 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Treatment-Resistant Depression
pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression
We aim to evaluate the safety and efficacy of pBFS-guided high-dose rTMS therapy with short inter-session interval for patients with treatment-resistant depression
- Trial name
- NCT05842291
- Testing
- Active rTMS with short inter-session interval, Active rTMS with long inter-session interval
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Changping Laboratory
Treatment Resistant Depression (TRD), Late Life Depression (LLD)
Lumateperone for Late-Life Depression
The purpose of this research study is to examine how well a medication called lumateperone (Caplyta) works to relieve depression in older adults with treatment-resistant depression. Lumateperone (Caplyta) is approved by the U.S.
- Conditions
- Treatment Resistant Depression (TRD), Late Life Depression (LLD), Depression / Major Depressive Disorder
- Trial name
- IRL Grey-C (NCT07623135)
- Testing
- Lumateperone
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Eric Lenze
Treatment Resistant Depression, Major Depressive Disorder
Predictors of Intravenous Ketamine Response in TRD
For patients with treatment-resistant depression (TRD), a single low dose of intravenous (IV) ketamine can help relieve symptoms as quickly as 24 hours later.
- Conditions
- Treatment Resistant Depression, Major Depressive Disorder, Bipolar Disorder
- Trial name
- NCT05625555
- Testing
- Ketamine, Midazolam
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Abraham Nunes
Major Depressive Disorder
High Dose Accelerated iTBS for Depression
This trial will compare active intermittent theta burst stimulation (iTBS) rTMS in an accelerated treatment schedule (8 treatment sessions per day for 5 days) to a placebo control.
- Trial name
- NCT04255784
- Testing
- Active iTBS
- Where
- 2 sites in Canada
- Volunteers
- 228 people
- Sponsor
- Centre for Addiction and Mental Health
Major Depressive Disorder, Recurrent Depressive Disorder
Deep Brain Stimulation in Patients With Chronic Treatment Resistant Depression
Major depressive disorders are real public health issues in terms of diagnosis and treatment. Some forms of depression are chronic and resistant to treatment (TRD). In these forms suicide risk is important.
- Conditions
- Major Depressive Disorder, Recurrent Depressive Disorder, Bipolar Disorder
- Trial name
- STHYM (NCT01973478)
- Testing
- DBS
- Where
- 5 sites in France
- Volunteers
- 9 people
- Sponsor
- Rennes University Hospital
Major Depressive Disorders
The Effects of Transcranial Magnetic Stimulation on Retina and Choroidal Structures
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMSEYE (NCT06615804)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Depression, Treatment Resistant Depression
Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression
SHAKTI (from the Sanskrit word for "power") is a 5-year natural history, longitudinal, prospective study of a cohort of 6,000 participants that will help uncover the socio-demographic, lifestyle, clinical, psychological, and…
- Conditions
- Depression, Treatment Resistant Depression, Mood Disorders, Bipolar Disorder
- Trial name
- SHAKTI (NCT06002204)
- Testing
- Observational Study
- Where
- United States
- Volunteers
- 6,000 people, healthy volunteers welcome
- Sponsor
- University of Texas Southwestern Medical Center
Bipolar Depression
Repetitive Transcranial Magnetic Stimulation for Treating Resistant Bipolar Depression
The aim of this randomized, single-blind trial is to evaluate the effectiveness and tolerability of high frequency or low frequency repetitive transcranial magnetic stimulation (rTMS) in patients with resistant bipolar…
- Trial name
- NCT01586793
- Testing
- Magstim Rapid2 Stimulator
- Where
- Canada
- Volunteers
- 8 people
- Sponsor
- Douglas Mental Health University Institute